Von Hippel-Lindau disease is a rare genetic disorder that causes tumors and cysts to develop throughout the body over a person’s lifetime, requiring careful monitoring and a coordinated approach to care from multiple medical specialists.
Understanding Von Hippel-Lindau Disease
Von Hippel-Lindau disease, often called VHL, is a rare genetic condition that significantly increases the likelihood that a person will develop certain types of tumors and cysts in various parts of their body. These growths can be either cancerous (meaning they can spread to other parts of the body) or noncancerous (meaning they stay in one place), but both types can cause serious health problems depending on where they grow and how large they become. The condition affects multiple organ systems, which means that people with VHL need to be monitored regularly throughout their lives to catch new tumors early and treat them before complications develop.[1]
The disease gets its name from two doctors who first described its characteristics more than a century ago. Eugen von Hippel, a German eye doctor, and Arvid Lindau, a Swedish pathologist, independently observed patterns of tumors in their patients’ eyes and brains. In the 1960s, researchers officially named the condition von Hippel-Lindau disease to honor their pioneering work in identifying this genetic disorder.[8]
How Common Is Von Hippel-Lindau Disease?
Von Hippel-Lindau disease is considered quite rare in the medical world. Studies estimate that the condition affects approximately one in every 36,000 people, though some research suggests the number could be closer to one in 91,000 individuals worldwide. This rarity means that many doctors may only encounter a handful of VHL patients during their entire careers, which is why specialized care centers that focus on this condition are so important for patients and their families.[2][4]
The disease affects males and females equally, showing no preference for one sex over the other. Similarly, VHL appears to occur at similar rates across different ethnic groups and geographic regions around the world. There are no known populations that are more or less likely to develop this condition based on where they live or their cultural background.[4]
Research shows that by the time people with the VHL genetic mutation reach age 65, approximately 97% of them will have developed at least one of the tumors or conditions associated with the disease. Most people with VHL begin experiencing symptoms during young adulthood, though the condition can affect individuals at any age. Many patients receive their diagnosis in their mid-twenties, though some are identified much earlier, particularly if they have a known family history of the condition.[1][3]
What Causes Von Hippel-Lindau Disease
Von Hippel-Lindau disease is caused by changes, called mutations (permanent alterations in the genetic instructions), in a specific gene known as the VHL gene. This gene is located on chromosome 3, which is one of the 23 pairs of chromosomes that contain all of our genetic information. The VHL gene is classified as a tumor suppressor gene (a type of gene that normally helps prevent cells from growing and dividing too rapidly), which means its job is to keep cells under control and prevent them from growing out of control.[2]
Every person is born with two copies of the VHL gene, one inherited from each parent. When the VHL gene works normally, it produces a protein called the VHL protein, which performs important housekeeping tasks inside cells. This protein helps regulate how cells respond to oxygen levels and how they use nutrients. It also plays a role in breaking down other proteins that promote cell growth, particularly proteins called hypoxia-inducible factors (proteins that tell cells to behave as if they don’t have enough oxygen).[12]
When someone has a mutation in their VHL gene, the gene either cannot produce the VHL protein at all, or it produces a version of the protein that doesn’t work properly. Without a functioning VHL protein, cells cannot properly regulate their growth and division. The cells act as though they are being starved of oxygen, even when plenty of oxygen is available. This triggers the accumulation of growth-promoting proteins that would normally be broken down, leading cells to grow and divide in an uncontrolled manner. Over time, this uncontrolled growth results in the formation of tumors and cysts characteristic of VHL disease.[2][4]
How Von Hippel-Lindau Disease Is Inherited
Von Hippel-Lindau disease follows what geneticists call an autosomal dominant (a pattern where only one altered gene copy is needed to increase disease risk) inheritance pattern. This means that a person only needs to inherit one mutated copy of the VHL gene to have an increased risk of developing tumors. If a parent has VHL, each of their children has a 50% chance of inheriting the mutated gene. The disease can be passed down through either the mother’s or father’s side of the family, as the VHL gene is not located on the sex chromosomes.[2][8]
Approximately 80% of people with VHL inherit the mutated gene from an affected parent. However, in about 20% of cases, the mutation occurs spontaneously, meaning it appears for the first time in that person without being inherited from either parent. This is called a de novo mutation (a new genetic change that occurs during the formation of egg or sperm cells or very early in development). Even when the mutation is new and not inherited, the person who has it can still pass it on to their own children.[2][4]
The way VHL causes tumors is somewhat unique among genetic conditions. Although people with VHL are born with one mutated copy of the VHL gene in every cell of their body, this alone is not enough to cause tumors to form. A second mutation must occur in the other copy of the VHL gene within a specific cell during the person’s lifetime. When both copies of the gene become non-functional in a particular cell, that cell loses all tumor suppression ability and can begin growing into a tumor. This is why people with VHL develop multiple tumors throughout their lives rather than all at once, and why tumors can appear in different organs at different times.[2][3]
Groups at Higher Risk
The primary risk factor for developing von Hippel-Lindau disease is having a family history of the condition. If one of your parents has VHL, you have a 50% chance of inheriting the genetic mutation that causes it. People who have siblings, parents, or children with VHL should consider genetic testing and counseling to understand their own risk and make informed decisions about screening and family planning.[2]
Because VHL can also occur as a spontaneous mutation, even people without any known family history can develop the condition. This is why doctors sometimes test for VHL when they encounter certain patterns of tumors, particularly when someone develops unusual tumors at a young age or develops the same type of tumor in multiple locations. For example, if someone develops kidney tumors in both kidneys before age 40, or develops brain tumors along with kidney tumors, doctors might suspect VHL even without a family history.[8]
Common Symptoms and How They Affect Daily Life
The symptoms someone experiences with von Hippel-Lindau disease depend entirely on where tumors develop in their body and how large they grow. Because VHL can cause tumors in multiple different organs, the range of possible symptoms is quite broad. Some people may have tumors that cause no symptoms at all and are only discovered during routine screening, while others may experience significant problems that affect their daily activities.[3]
Brain and Spinal Cord Symptoms
One of the most common tumor types in VHL is called a hemangioblastoma (a noncancerous tumor made of newly formed blood vessels). These tumors most frequently develop in the cerebellum, which is the part of the brain that controls balance and coordination, as well as in the spinal cord. Between 44% and 72% of people with VHL develop hemangioblastomas in their cerebellum, while 13% to 59% develop them in the spinal cord.[3]
When hemangioblastomas grow in the brain, they can cause persistent headaches, nausea, and vomiting. People may experience problems with their balance and walking, a condition doctors call ataxia (loss of full control over bodily movements), or they might feel dizzy and unsteady on their feet. Some individuals notice weakness in their arms or legs. Spinal hemangioblastomas typically cause back or neck pain first, which can be accompanied by numbness, tingling, or weakness in the limbs. If these tumors grow large enough, they can compress the spinal cord and cause more serious problems with sensation and movement.[2][3]
Eye Problems
The eyes are often among the first organs affected by VHL, with retinal hemangioblastomas developing in 45% to 60% of people with the condition. These tumors grow in the retina, which is the light-sensitive tissue at the back of the eye that allows us to see. Early on, retinal hemangioblastomas may not cause any symptoms, which is why regular eye examinations are so important for people with VHL. As these tumors grow, they can cause vision problems ranging from seeing spots or floaters to significant vision loss or even blindness if left untreated. Some people experience blurred vision, while others may notice blind spots in their field of vision.[1][3]
Kidney-Related Symptoms
The kidneys are frequently affected by VHL, with cysts developing in 59% to 63% of patients. More seriously, between 24% and 45% of people with VHL develop clear cell renal cell carcinoma (the most common type of kidney cancer). In fact, kidney cancer is the leading cause of death in people with von Hippel-Lindau disease, which makes monitoring and early treatment of kidney tumors critically important. Many kidney tumors do not cause symptoms in their early stages, which is why regular imaging tests are essential. When symptoms do appear, they might include blood in the urine, pain in the side or back, or a noticeable lump in the abdomen.[1][3]
Adrenal Gland Tumors
Between 10% and 20% of people with VHL develop tumors in their adrenal glands called pheochromocytomas (tumors that produce excessive amounts of adrenaline and related hormones). These tumors can sometimes produce no symptoms at all, but in other cases, they release large amounts of hormones that cause high blood pressure, severe headaches, rapid heartbeat, excessive sweating, and anxiety or panic attack-like episodes. Pheochromocytomas can be particularly dangerous during times of physical stress, such as surgery, accidents, or pregnancy, because they can cause sudden, severe spikes in blood pressure.[1][2]
Pancreatic Tumors and Cysts
Pancreatic cysts are extremely common in VHL, affecting between 50% and 91% of patients. Most of these cysts don’t cause any symptoms and don’t require treatment. However, between 5% and 17% of people with VHL develop pancreatic neuroendocrine tumors (rare tumors that start in the hormone-producing cells of the pancreas), which can potentially cause more serious problems. Fortunately, most pancreatic lesions in VHL remain asymptomatic and rarely cause problems with the pancreas’s ability to produce digestive enzymes or regulate blood sugar.[1][3]
Ear Problems
Between 10% and 25% of people with VHL develop rare tumors in their inner ear called endolymphatic sac tumors (growths that can affect hearing and balance). These tumors can cause hearing loss that ranges from mild to severe, ringing in the ears (called tinnitus), problems with balance, and dizziness. If these tumors are not detected and treated early, they can cause sudden and profound deafness.[1][2]
Reproductive System Tumors
Males with VHL may develop tumors called epididymal cystadenomas (growths in the small tube-like structure near the testicles that stores sperm), which occur in 25% to 60% of affected men. These tumors rarely cause problems unless they develop on both sides, in which case they might affect fertility. Females with VHL may develop tumors in the broad ligament near the fallopian tubes, affecting about 10% of women with the condition. These tumors, called broad ligament cystadenomas, are typically found during imaging studies done for other reasons.[1][3]
Preventing Complications Through Screening
While there is currently no way to prevent von Hippel-Lindau disease itself from developing in someone who carries the genetic mutation, regular screening and monitoring can catch tumors early when they are easier to treat and less likely to cause complications. This approach, called surveillance (regular monitoring for early signs of disease), is the cornerstone of managing VHL and can significantly improve outcomes and quality of life for people with the condition.[4]
Genetic testing plays a crucial role in prevention strategies for families affected by VHL. When one family member is diagnosed with the condition, genetic testing can identify which other family members carry the mutation and therefore need regular screening. This allows for early detection and intervention, often before symptoms appear. People who test negative for the family’s specific VHL mutation can be spared the anxiety and expense of lifelong screening, while those who test positive can begin appropriate monitoring protocols.[13]
For individuals known to have VHL or who carry the genetic mutation, comprehensive screening programs should begin in childhood. Recommendations include annual eye examinations starting in infancy or early childhood, annual general health checks that include blood pressure monitoring and measurement of specific hormones in the blood, and periodic imaging studies of the brain, spine, and abdomen. The specific timing and frequency of different screening tests depends on the person’s age and whether they have already developed any tumors.[4]
Current surveillance guidelines recommend that children ages 0 to 4 years receive annual retinal inspections and general pediatric examinations. Between ages 5 and 14, screening expands to include annual blood tests to check for hormones that might indicate adrenal tumors, with brain and spinal imaging added around age 10. From age 15 onward, people with VHL should have annual eye examinations and neurological evaluations, imaging of the brain and spine every two years, and regular imaging of the abdomen to monitor the kidneys, pancreas, and adrenal glands. Hearing tests are also recommended every two years starting at age 5.[4]
How Tumors Develop: Understanding the Disease Process
The biological process that leads to tumor formation in von Hippel-Lindau disease involves a complex cascade of events at the cellular level. Understanding this process helps explain why the disease causes multiple tumors over time and why they develop in specific types of tissues.[2]
In healthy cells, the VHL protein works as part of a larger protein complex that has a specific job: to mark other proteins for destruction when they are no longer needed. One of the most important proteins that VHL helps control is called HIF, or hypoxia-inducible factor. HIF is a type of transcription factor (a protein that controls whether other genes are turned on or off). When oxygen levels in tissues are normal, the VHL protein helps tag HIF for breakdown and removal from the cell. This prevents HIF from accumulating and causing problems.[4]
When the VHL gene is mutated, the VHL protein either doesn’t exist or doesn’t work properly. Without functional VHL protein, HIF accumulates inside cells even when oxygen is plentiful. High levels of HIF trick the cell into thinking it is being deprived of oxygen. In response, HIF turns on genes that promote the formation of new blood vessels (a process called angiogenesis), increase cell division, and alter how cells use energy. All of these changes help cells survive in low-oxygen conditions, but when they happen inappropriately, they can lead to tumor formation.[12]
Research has shown that one particular form of HIF, called HIF-2α, plays an especially critical role in causing tumors to grow in VHL disease, particularly kidney tumors. This discovery led to the development of targeted drugs that can specifically block HIF-2α’s activity, offering new treatment options for people with VHL. The tumors that develop in VHL tend to be highly vascular, meaning they contain many blood vessels. This characteristic reflects the effect of uncontrolled HIF activity promoting blood vessel formation.[12]
The hemangioblastomas that are characteristic of VHL are essentially masses of newly formed, abnormal blood vessels. Although these tumors are noncancerous and do not spread to other parts of the body like cancer does, they can still cause significant problems. As they grow, they can press on surrounding tissues, particularly in confined spaces like the brain and spinal cord. They can also leak fluid or bleed, creating additional pressure and damage to nearby structures.[1]
In the kidneys, the loss of VHL function leads to a particular type of cancer called clear cell renal cell carcinoma. This cancer gets its name from how the cells appear under a microscope – they look clear rather than pink because they accumulate fats and sugars. This is a direct result of the metabolic changes caused by uncontrolled HIF activity. Without VHL protein to keep cell growth in check, kidney cells can transform into cancer and begin to spread if not caught and treated early.[1]
